TrialThe Journal of clinical investigation2018

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Peter Ulrichts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.